GlassScriptPhysician profile
Lawrence G Vanhorn
NPI 1780631036
$1,853.03
in general payments reported to CMS, 2019-2025
27 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $86.10 · 2022: $41.85 · 2023: $311 · 2024: $531 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.56 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.92 | 2019-2024 | |
| Radius Health, INC. | $173.45 | 2019-2024 | |
| Hologic Sales and Service, LLC | $139.08 | 2024 | Acessa Provu System |
| Bayer Healthcare Pharmaceuticals INC. | $135.33 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $120.87 | 2023-2024 | |
| Roche Diagnostics Corporation | $115.43 | 2019-2020 | |
| Exact Sciences Corporation | $114.33 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $109.43 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $107.26 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $85.78 | 2023-2025 | Veozah |
| Amgen INC. | $84.55 | 2024-2025 | Evenity, Prolia |
| Allergan, INC. | $67.19 | 2019 | |
| Organon LLC | $56.66 | 2024-2025 | Nexplanon |
| Coopersurgical, INC. | $56.39 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $51.76 | 2024-2025 | Phexxi, Solosec, Phexx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.67 | 2025 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $31.28 | 2023 | Seglentis, Livalo |
| Boston Scientific Corporation | $19.66 | 2019 | |
| Davol INC. | $18.35 | 2020 | |
| Horizon Therapeutics Plc | $17.06 | 2019 | |
| Daiichi Sankyo INC. | $15.47 | 2024 | Injectafer |
| Celularity INC. | $15.23 | 2020 | |
| Dynavax Technologies Corporation | $14.74 | 2025 | Heplisav-B |
| Exeltis, USA INC. | $14.54 | 2019 | |
| Millicent US INC | $14.24 | 2019 | |
| Merck Sharp & Dohme LLC | $13.74 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Vanhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.